Brief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
26/01/2026 21:40
Jan 26 (Reuters) - Autolus Therapeutics PLC 6A3Ay.F: AUTOLUS THERAPEUTICS PLC - UNIT ENTERS MASTER SERVICE AGREEMENT WITH AGC BIOLOGICS - SEC FILING AUTOLUS THERAPEUTICS PLC: AGREEMENT FOR MANUFACTURE AND SUPPLY OF LENTIVIRAL VECTOR AUTOLUS THERAPEUTICS PLC - AGREEMENT RUNS FOR TEN YEARS, TERMINABLE FOR DEFAULT - SEC FILING AUTOLUS THERAPEUTICS PLC - UNDER DEAL, TO PURCHASE MINIMUM OF 14 BATCHES OF LENTIVIRAL VECTOR DURING FIRST 2 CALENDAR YEARS - SEC FILING AUTOLUS THERAPEUTICS PLC - TO PURCHASE MINIMUM EUR 25 MILLION OF PRODUCTS AND SERVICES - SEC FILING Further company coverage: [6A3Ay.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants